Call for 10,000 vac­cine vols

New York Daily News - - CORONAVIRU­S OUTBREAK -

Ox­ford Univer­sity wants peo­ple will­ing to give it a shot.

The univer­sity has put out a call for more than 10,000 vol­un­teers will­ing to be im­mu­nized with its ex­per­i­men­tal coro­n­avirus vac­cine to de­ter­mine whether it could be a vi­able so­lu­tion for the sweep­ing global pan­demic.

Sci­en­tists at the ven­er­a­ble in­sti­tu­tion be­gan vac­ci­nat­ing the first round of 1,000 healthy vol­un­teers in April as part the ini­tial phase of clin­i­cal tri­als. On Fri­day, Ox­ford re­vealed re­searchers are pre­pared to move into more ad­vanced stud­ies, which re­quires 10,260 adult and chil­dren par­tic­i­pants from around the United King­dom.

The trial vac­cine, called AZD1222, was ini­tially tested on six macaque mon­keys in the United States be­fore de­liv­er­ing promis­ing re­sults on the first two hu­mans in Ox­ford back on April 23.

“The clin­i­cal stud­ies are pro­gress­ing very well,” Prof. An­drew Pol­lard, head of the Ox­ford Vac­cine Group, said in a news re­lease.

“We are now ini­ti­at­ing stud­ies to eval­u­ate how well the vac­cine in­duces im­mune re­sponse in older adults, and to test whether it can pro­vide pro­tec­tion to the wider pop­u­la­tion.”

Sci­en­tists hope to be­gin their sec­ond wave of test im­mu­niza­tions on thou­sands of new peo­ple, in­clud­ing the el­derly, in May and June, ac­cord­ing to the re­lease.

The po­ten­tial treat­ment was de­vel­oped from a weak­ened strain of the com­mon cold that causes in­fec­tions in chim­panzees but has been ge­net­i­cally al­tered so it is im­pos­si­ble to repli­cate in hu­mans. Re­searchers said the harm­less dis­ease is then used to spread a “Spike pro­tein,” which pre­vents COVID-19 from en­ter­ing hu­man cells.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.